**Patient Name** Mrs. SUSHILA MEENA Lab No 4024972 **UHID** 40010809 Sample Date 24/02/2024 3:17PM Age/Gender 34 Yrs/Female **Report Date** 24/02/2024 3:29PM Prescribed By Dr. EHS CONSULTANT Bed No / Ward OPD **Referred By** Dr. EHS CONSULTANT **Report Status** Final Company Mediwheel - Arcofemi Health Care Ltd.

### **CYTOLOGY**

CYTOLOGY\*

Type of Specimen Pap smear (Conventional)

No. of smears examined Two

Satisfactory for evaluation.

Adequacy Adequate Endocervical cells Seen.

Inflammation Mild acute inflammation

Organisms Not seen Epithelial cell abnormality Not seen

Others -

**Impression** Negative for intraepithelial lesion / malignancy.

Note: Test marked as \* are not accredited by NABL

Bethesda2014

-----\*\* End Of Report \*\*------

Dr. ABHINAY VERMA
MBBS|MD|INCHARGE PATHOLOGY

0

Mrs. SUSHILA MEENA **Patient Name** Lab No 4024972 UHID 40010809 **Collection Date** 24/02/2024 10:09AM 24/02/2024 10:22AM Age/Gender 34 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 24/02/2024 4:50PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9950955558

### **BIOCHEMISTRY**

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: Fl. Plasma

 BLOOD GLUCOSE (FASTING)
 79.0
 mg/dl
 71 - 109

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP ) 92 mg/dl Non – Diabetic: - < 140 mg/dl

Pre – Diabetic: - 140-199 mg/dl Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

THYROID T3 T4 TSH Sample: Serum

Т3	1.470	ng/mL	0.970 - 1.690
Т4	7.10	ug/dl	5.53 - 11.00
TSH	2.44	μIU/mL	0.40 - 4.05

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name	Mrs. SUSHILA MEENA	Lab No	4024972
UHID	40010809	Collection Date	24/02/2024 10:09AM
Age/Gender IP/OP Location	34 Yrs/Female	Receiving Date	24/02/2024 10:22AM
	O-OPD	Report Date	24/02/2024 4:50PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9950955558		

#### **BIOCHEMISTRY**

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

 $Interpretation: -The \ determination \ of \ T3 \ is \ utilized \ in \ the diagnosis \ of \ T3-hyperthyroidism \ the \ detection \ of \ early \ stages \ of hyperthyroidism \ and \ for \ indicating \ a \ diagnosis \ of \ thyrotoxicosis \ factitia.$ 

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

1.3 L

10.0

Interpretation:—The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.38	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.25	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.13	mg/dl	0.00 - 0.30	
SGOT	21.0	U/L	0.0 - 32.0	
SGPT	18.4	U/L	0.0 - 33.0	
TOTAL PROTEIN	7.5	g/dl	6.6 - 8.7	
ALBUMIN	4.2	g/dl	3.5 - 5.2	
GLOBULIN	3.3		1.8 - 3.6	
ALKALINE PHOSPHATASE	96.0	U/L	35 - 104	

Ratio

U/L

1.5 - 2.5

0.0 - 40.0

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

A/G RATIO

GGTP

MBBS | MD | INCHARGE PATHOLOGY

Page: 2 Of 11

**Patient Name** Mrs. SUSHILA MEENA Lab No 4024972 UHID **Collection Date** 24/02/2024 10:09AM 40010809 24/02/2024 10:22AM Age/Gender **Receiving Date** 34 Yrs/Female Report Date O-OPD **IP/OP Location** 24/02/2024 4:50PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9950955558

#### **BIOCHEMISTRY**

**BILIRUBIN TOTAL** :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Bivret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

#### LIPID PROFILE

TOTAL CHOLESTEROL	173		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	49.2		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	113.3		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	13	mg/dl	10 - 50
TRIGLYCERIDES	65		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	4	%	

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

**Patient Name** Mrs. SUSHILA MEENA Lab No 4024972 UHID 40010809 **Collection Date** 24/02/2024 10:09AM 24/02/2024 10:22AM Age/Gender **Receiving Date** 34 Yrs/Female **Report Date IP/OP Location** O-OPD 24/02/2024 4:50PM

**Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9950955558

#### **BIOCHEMISTRY**

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease. LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	22.8	mg/dl	16.60 - 48.50
BUN	11	mg/dl	6 - 20
CREATININE	0.51	mg/dl	0.50 - 0.90
SODIUM	135 L	mmol/L	136 - 145
POTASSIUM	3.97	mmol/L	3.50 - 5.50
CHLORIDE	102	mmol/L	98 - 107
URIC ACID	2.6	mg/dl	2.4 - 5.7
CALCIUM	8.6	mg/dl	8.60 - 10.00

**RESULT ENTERED BY: Mr. JITENDRA MARWAL** 

Dr. ABHINAY VERMA

**Patient Name** Mrs. SUSHILA MEENA Lab No 4024972 UHID **Collection Date** 24/02/2024 10:09AM 40010809 24/02/2024 10:22AM Age/Gender **Receiving Date** 34 Yrs/Female Report Date O-OPD **IP/OP Location** 24/02/2024 4:50PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9950955558

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.

POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM: - Method: ISE electrode. Interpretation: -Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA: Method: Urease/GLDH kinetic assay. Interpretation: -Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Mrs. SUSHILA MEENA **Patient Name** Lab No 4024972 UHID 40010809 **Collection Date** 24/02/2024 10:09AM 24/02/2024 10:22AM Age/Gender **Receiving Date** 34 Yrs/Female **Report Date IP/OP Location** O-OPD 24/02/2024 4:50PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9950955558

### **BLOOD BANK INVESTIGATION**

**Biological Ref. Range Test Name** Result Unit

**BLOOD GROUPING** "A" Rh Positive

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

**RESULT ENTERED BY: Mr. JITENDRA MARWAL** 

Dr. ABHINAY VERMA

Patient Name Mrs. SUSHILA MEENA Lab No 4024972 **Collection Date** 24/02/2024 10:09AM UHID 40010809 24/02/2024 10:22AM Age/Gender **Receiving Date** 34 Yrs/Female **Report Date** O-OPD **IP/OP Location** 24/02/2024 4:50PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9950955558

### **CLINICAL PATHOLOGY**

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION	0.7			
VOLUME	35	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	6.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	0-1	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	1-3	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Mrs. SUSHILA MEENA **Patient Name** Lab No 4024972 UHID 40010809 **Collection Date** 24/02/2024 10:09AM 24/02/2024 10:22AM Age/Gender 34 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 24/02/2024 4:50PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9950955558

### **CLINICAL PATHOLOGY**

NIL **BACTERIA** NIL **OHTERS** NIL NIL

Methodology:-

Methodology:Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific
Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue
(Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method.
interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

**RESULT ENTERED BY: Mr. JITENDRA MARWAL** 

Dr. ABHINAY VERMA

**Patient Name** Mrs. SUSHILA MEENA Lab No 4024972 UHID 40010809 **Collection Date** 24/02/2024 10:09AM 24/02/2024 10:22AM Age/Gender **Receiving Date** 34 Yrs/Female Report Date **IP/OP Location** O-OPD 24/02/2024 4:50PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9950955558

#### **HEMATOLOGY**

Test Name	Result	Unit	Biological Ref. Ra	nge
CBC (COMPLETE BLOOD COUNT)				Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	9.5 L	g/dl	12.0 - 15.0	
PACKED CELL VOLUME(PCV)	32.3 L	%	36.0 - 46.0	
MCV	78.8 L	fl	82 - 92	
MCH	23.2 L	pg	27 - 32	
MCHC	29.4 L	g/dl	32 - 36	
RBC COUNT	4.10	millions/cu.mm	3.80 - 4.80	
TLC (TOTAL WBC COUNT)	6.62	10^3/ uL	4 - 10	
DIFFERENTIAL LEUCOCYTE COUNT				
NEUTROPHILS	58.3	%	40 - 80	
LYMPHOCYTE	34.1	%	20 - 40	
EOSINOPHILS	1.7	%	1 - 6	
MONOCYTES	5.3	%	2 - 10	
BASOPHIL	0.6 L	%	1 - 2	
PLATELET COUNT	2.66	lakh/cumm	1.500 - 4.500	

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method:- Calculation bysysmex. MCH: - Method: - Calculation bysysmex.
MCHC: - Method: - Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry LYMPHOCYTS : - Method: Optical detectorblock based on FlowcytometryEOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry

BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis. HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

**ESR (ERYTHROCYTE SEDIMENTATION RATE)** 40 H mm/1st hr 0 - 15

**RESULT ENTERED BY: Mr. JITENDRA MARWAL** 

Dr. ABHINAY VERMA

Mrs. SUSHILA MEENA **Patient Name** Lab No 4024972 24/02/2024 10:09AM UHID 40010809 **Collection Date** 24/02/2024 10:22AM Age/Gender **Receiving Date** 34 Yrs/Female **Report Date IP/OP Location** O-OPD 24/02/2024 4:50PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9950955558

Method:-Modified Westergrens.
Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Page: 10 Of 11

Mrs. SUSHILA MEENA 4024972 **Patient Name** Lab No UHID 40010809 **Collection Date** 24/02/2024 10:09AM 24/02/2024 10:22AM Age/Gender **Receiving Date** 34 Yrs/Female **Report Date IP/OP Location** O-OPD 24/02/2024 4:50PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9950955558

X Ray

Test Name Result Unit Biological Ref. Range

### X-RAY CHEST P. A. VIEW

Both lung fields are clear.

Both CP angles are clear.

Both hemi-diaphragms are normal in shape and outlines.

Cardiac shadow is within normal limits.

Visualized bony thorax is unremarkable.

Correlate clinically & with other related investigations.

\*\*End Of Report\*\*

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. RENU JADIYA MBBS, DNB RADIOLOGIST

Page: 11 Of 11

## **DEPARTMENT OF RADIO DIAGNOSIS**

UHID / IP NO	40010809 (5205)	RISNo./Status:	4024972/
Patient Name:	Mrs. SUSHILA MEENA	Age/Gender:	34 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No:	24/02/2024 9:37AM/ OPSCR23- 24/13884	Scan Date :	
Report Date :	24/02/2024 11:49AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

#### **ULTRASOUND STUDY OF WHOLE ABDOMEN**

Liver: Normal in size & echotexture. No obvious significant focal parenchymal mass lesion

noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.

**Gall Bladder:** Lumen is clear. Wall thickness is normal. CBD is normal.

**Pancreas:** Normal in size & echotexture.

**Spleen:** Normal in size & echotexture. No focal lesion seen.

Right Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Left Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Urinary Bladder: Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall

thickness is normal.

**Uterus:** Normal in size, shape & anteverted in position. Endometrial thickness is normal.

Endometrial cavity is empty. No mass lesion is seen. Cervix is normal.

**Both ovaries:** Bilateral ovaries are normal in size, shape & volume. **Others:** No significant free fluid is seen in pelvic peritoneal cavity.

IMPRESSION: USG findings are suggestive of

• No significant sonographic abnormality noted.

Correlate clinically & with other related investigations.

DR. APOORVA JETWANI

Incharge & Senior Consultant Radiology

MBBS, DMRD, DNB

Reg. No. 26466, 16307

# **DEPARTMENT OF CARDIOLOGY**

UHID / IP NO	40010809 (5205)	RISNo./Status:	4024972/
Patient Name:	Mrs. SUSHILA MEENA	Age/Gender:	34 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No:	24/02/2024 9:37AM/ OPSCR23- 24/13884	Scan Date :	
Report Date:	24/02/2024 11:57AM	Company Name:	Final

REFERRAL REASON: HEALTH CHECKUP

### 2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

### **M MODE DIMENSIONS: -**

Normal Normal								
IVSD	10.1		6-1	2mm		LVIDS	26.0	20-40mm
LVIDD	39.0		32-	57mm		LVPWS	15.4	mm
LVPWD	10.1		6-1	2mm		AO	30.8	19-37mm
IVSS	15.4		j	mm		LA	30.3	19-40mm
LVEF	60-62		>:	55%		RA	-	mm
	DOPPLEF	R MEA	SUREN	1ENTS &	& CALC	ULATIONS	<u>:</u>	
STRUCTURE	MORPHOLOGY	VELOCITY (m/s)		GRADIENT		REGURGITATION		
		` ′			(mmHg)			
MITRAL	NORMAL	E	1.09	e'	-	-		NIL
VALVE		A	0.67	E/e'	-			
TRICUSPID	NORMAL		E	0.	66	RVSP 33mmHg		MILD TR
VALVE			A	0.:	59			
		0.37						
AORTIC	NORMAL	1.07			-		NIL	
VALVE								
PULMONARY	NORMAL	0.64					NIL	
VALVE						-		

### **COMMENTS & CONCLUSION: -**

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 60-62%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- MILD TR/PAH, OTHER CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - MILD TR/PAH, NORMAL BI VENTRICULAR FUNCTIONS

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

Patient Name Mrs. SUSHILA MEENA

**UHID** 341092

**Age/Gender** 34 Yrs/Female

IP/OP Location O-OPD

Referred By Dr. EHCC Consultant

**Mobile No.** 9773349797

Lab No 634764 Collection Date 24/02/2

 Collection Date
 24/02/2024 12:19PM

 Receiving Date
 24/02/2024 12:24PM

**Report Date** 24/02/2024 1:20PM

Report Status Final



### **BIOCHEMISTRY**

Test Name	Result	Unit	Biological Ref. Range
			Sample: WHOLE BLOOD EDTA
HBA1C	5.3	%	< 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes
			Known Diabetic Patients < 7 % Excellent Control 7 - 8 % Good Control > 8 % Poor Control

Method: - Tetradecyltrimethylammonium bromide
Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient.
The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

\*\*End Of Report\*\*

RESULT ENTERED BY : Mr. Ravi

Dr. SURENDRA SINGH CONSULTANT & HOD MBBS|MD| PATHOLOGY Dr. ASHISH SHARMA
CONSULTANT & INCHARGE PATHOLOGY
MBBS|MD| PATHOLOGY

Page: 1 Of 1